ENTITY
SMARTSCORE: 2.2/5

VISEN Pharmaceuticals (2561 HK)

8
Analysis
Health CareChina
VISEN Pharmaceuticals develops biopharmaceutical technology focused on treatments in selected endocrinology diseases. The Company provides lonapegsomatropin, navepegritide, palopegteriparatide, and other treatments. VISEN Pharmaceuticals conducts businesses in China.
more
24 Mar 2025 00:25

ECM Weekly (24th Mar 2025) -JX Advance, DN Solutions, Nanshan Aluminimum, Anthem, EAAA, Judo Capital

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
297 Views
Share
bullishJapan Post Bank
02 Mar 2025 23:45

ECM Weekly (3rd Mar 2025) - Japan Post Bank, JX Advance, Mixue, Chifeng, JSW Cement, Premier, Guzman

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
436 Views
Share
bullishLG CNS
03 Feb 2025 00:48

ECM Weekly (3rd Feb 2025) - Seoul Guarantee, Dr Agarwal's, Ather Energy, Hexaware, Visen Pharma

Aequitas Research's weekly update on the IPOs, placements, lockup expiry and other ECM linked events that were covered by the team over the past week.

Logo
445 Views
Share
19 Oct 2023 00:55

Pre-IPO VISEN Pharmaceuticals - The Product Pipeline and the Key Risks

VISEN’s pipeline has strength, but fierce competition/VBP/increasingly stringent regulatory environment will bring challenges to...

Logo
527 Views
Share
x